Biological systems: patients
. | . | . | . | . | . | . | . | . | GBA¶ . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample ID . | Sex . | Age, y . | Risk* . | Molecular diagnosis† . | MRD‡ . | WBC g/L . | Immunophenotype§ . | Clustering|| . | 0 h . | 6 h . | 24 h . | ||
| T-ALL-2 | M | 8.5 | SR | NAD | LR | 30.9 | CD3, 4, 5, 8, 10 | T-ALL | 62.5 | 189.6 | 179.8 | ||
| T-ALL-20 | M | 5 | MR | NAD | IR | 135.6 | CD2, 3, 5, 7 | T-ALL | 48.7 | 110.7 | 139.0 | ||
| T-ALL-25 | F | 10.3 | MR | t(8:14)(q24:11) | IR | 66.8 | CD2, 3, 5, 7, 8 | T-ALL | 78.4 | 85.8 | 197.2 | ||
| B-ALL-13 | M | 5.9 | SR | t(8:14)(q24:11) | LR | 13.4 | CD10, 13, 19, 34 | Not assigned | 62.3 | 66.4 | 77.6 | ||
| B-ALL-17 | F | 14.7 | DBA | Hyperploidy >50 | DBD | 44 | CD10, 13, 19, 33, 34 | Hyperploidy | 37.1 | 94.9 | 132.5 | ||
| B-ALL-24 | F | 2.6 | HR | Low hyperploidy | IR | 8.3 | CD10, 19, 34 | Not assigned | 50.9 | 64.6 | 89.6 | ||
| B-ALL-31 | F | 17.2 | MR | Hyperploidy >50 | IR | 8.6 | CD10, 19, 34 | Hyperploidy | 64.9 | 88.8 | 114.6 | ||
| B-ALL-32 | F | 3.7 | MR | t(4:8), TEL/AML | IR | 26.4 | CD19 | TEL-AML | 54.4 | 114.2 | 100.7 | ||
| B-ALL-33 | M | 2.5 | MR | Low hyperploidy | IR | 79.3 | CD10, 19, 34 | Hyperploidy | 38.2 | 151.2 | 65.2 | ||
| B-ALL-37 | F | 15.1 | MR | Low hyperploidy | IR | 4.1 | CD10, 19, HL-DR | Not assigned | 69.5 | 77.1 | 124.3 | ||
| B-ALL-38 | M | 3.2 | MR | TEL/AML | IR | 5 | CD10, 19 | TEL-AML | 43.2 | 119.4 | 92.4 | ||
| B-ALL-40 | M | 17.3 | HR | NAD | HR | 82.5 | CD10, 19, 34 | Not assigned | 76.6 | 130.9 | 131.3 | ||
| B-ALL-43 | F | 1.6 | SR | NAD | ND | 53.1 | CD10, 19 | TEL-AML | 50.9 | 71.7 | 116.1 | ||
| Adult-BCP | M | 72.4 | NA | ND | NA | 16.2 | CD19; IgG3# | ND | 86.9 | 120.0 | 112.9 | ||
. | . | . | . | . | . | . | . | . | GBA¶ . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample ID . | Sex . | Age, y . | Risk* . | Molecular diagnosis† . | MRD‡ . | WBC g/L . | Immunophenotype§ . | Clustering|| . | 0 h . | 6 h . | 24 h . | ||
| T-ALL-2 | M | 8.5 | SR | NAD | LR | 30.9 | CD3, 4, 5, 8, 10 | T-ALL | 62.5 | 189.6 | 179.8 | ||
| T-ALL-20 | M | 5 | MR | NAD | IR | 135.6 | CD2, 3, 5, 7 | T-ALL | 48.7 | 110.7 | 139.0 | ||
| T-ALL-25 | F | 10.3 | MR | t(8:14)(q24:11) | IR | 66.8 | CD2, 3, 5, 7, 8 | T-ALL | 78.4 | 85.8 | 197.2 | ||
| B-ALL-13 | M | 5.9 | SR | t(8:14)(q24:11) | LR | 13.4 | CD10, 13, 19, 34 | Not assigned | 62.3 | 66.4 | 77.6 | ||
| B-ALL-17 | F | 14.7 | DBA | Hyperploidy >50 | DBD | 44 | CD10, 13, 19, 33, 34 | Hyperploidy | 37.1 | 94.9 | 132.5 | ||
| B-ALL-24 | F | 2.6 | HR | Low hyperploidy | IR | 8.3 | CD10, 19, 34 | Not assigned | 50.9 | 64.6 | 89.6 | ||
| B-ALL-31 | F | 17.2 | MR | Hyperploidy >50 | IR | 8.6 | CD10, 19, 34 | Hyperploidy | 64.9 | 88.8 | 114.6 | ||
| B-ALL-32 | F | 3.7 | MR | t(4:8), TEL/AML | IR | 26.4 | CD19 | TEL-AML | 54.4 | 114.2 | 100.7 | ||
| B-ALL-33 | M | 2.5 | MR | Low hyperploidy | IR | 79.3 | CD10, 19, 34 | Hyperploidy | 38.2 | 151.2 | 65.2 | ||
| B-ALL-37 | F | 15.1 | MR | Low hyperploidy | IR | 4.1 | CD10, 19, HL-DR | Not assigned | 69.5 | 77.1 | 124.3 | ||
| B-ALL-38 | M | 3.2 | MR | TEL/AML | IR | 5 | CD10, 19 | TEL-AML | 43.2 | 119.4 | 92.4 | ||
| B-ALL-40 | M | 17.3 | HR | NAD | HR | 82.5 | CD10, 19, 34 | Not assigned | 76.6 | 130.9 | 131.3 | ||
| B-ALL-43 | F | 1.6 | SR | NAD | ND | 53.1 | CD10, 19 | TEL-AML | 50.9 | 71.7 | 116.1 | ||
| Adult-BCP | M | 72.4 | NA | ND | NA | 16.2 | CD19; IgG3# | ND | 86.9 | 120.0 | 112.9 | ||
SR indicates standard risk; NAD, nothing abnormal detected in the above assays; LR, low risk; MR, medium risk; IR, intermediate risk; DBA, died before risk assignment; HR, high risk; ND, not done; and NA, not applicable.
Risk group assignment according to the BFM 2000 protocol (BFM-ALL Study Group): SR indicates standard risk (prednisolone good response, as well as complete cytomorphologic bone marrow remission on day 33, and neither BCR/ABL nor MLL/AF4, and MRD-negative on day 33); MR, medium risk (as standard but MRD-positive on day 33); HR, high risk (prednisolone poor response or Bcr/Ab1 or MLL/AF4 or MRD-positive on day 77)
Molecular diagnosis included ploidy determination by standard karyotyping, detection of BCR/ABL, BCR/ABL1, E2A/PBX1, MLL-1/AF-4, TEL/AML, SIL/TAL translocations by PCR and reconfirmation by in situ hybridization
Risk assignment according to MRD (minimal residual disease) detection by T-cell receptor or immunoglobulin rearrangement-specific PCR
CD marker expression in 80% or more of blasts as determined by direct immunofluorescence and FACS analysis
Entity assignment by gene clustering according to Ross et al33 (Figure S2)
GC bioactivity in nM cortisol equivalents: means of 2 measurements at 0, 6, and 24 hours
Data derived from expression profiling only